{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:25:22Z","timestamp":1787239522631,"version":"build-2736575974"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Precision oncology biomarker testing informs prognosis and guides treatment selection. These tests represent a growing component of cancer care costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study of US commercial payer-negotiated rates for biomarker tests for breast, colon, and non-small cell lung cancer, using Turquoise Health hospital pricing database. Outcomes included geographically adjusted payer-negotiated rates, within- and between-hospital price variation, and differences by payer, rurality, and hospital size, assessed using generalized linear models adjusted for multiple comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 422 515 negotiated rates for 28 biomarker tests across 2142 hospitals. Median proportion of hospitals reporting payer-negotiated rates was 18.3% (interquartile range [IQR]:17.2%-18.8%) for panel-based and 30.3% (IQR:22.2%-37.8%) for non-panel-based tests; median negotiated rates per test were $3704 (IQR: $3096-$4129) and $301 (IQR: $157-$485), respectively. Negotiated rates varied within hospitals (median within-hospital ratios: panel-based tests, 1.5 [IQR:1.4-1.5]; non-panel-based tests, 1.6 [IQR: 1.5-1.7]) and between hospitals (median between-hospital ratios: panel-based tests, 5.5 [IQR: 5.5-5.6]; non-panel-based tests, 5.2 [IQR: 5.1-5.4]). Negotiated rates varied significantly by payer for all tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings revealed wide variation in commercial payer-negotiated rates for oncology biomarker tests, underscoring the need for pricing transparency and efforts to reduce price variation to support equitable, affordable cancer care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/haschl\/qxag203","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:49:25Z","timestamp":1785930565000},"source":"Crossref","is-referenced-by-count":0,"title":["Commercial price variation in precision oncology testing across US hospitals"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-494X","authenticated-orcid":false,"given":"Maryam","family":"Mooghali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-4277","authenticated-orcid":false,"given":"Joshua J","family":"Skydel","sequence":"additional","affiliation":[{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Section of Rheumatology, Allergy & Immunology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9196","authenticated-orcid":false,"given":"Stacie B","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine , Nashville, TN 37203 ,","place":["United States"]},{"name":"Department of Medicine, Vanderbilt-Ingram Cancer Center , Nashville, TN 37232 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-361X","authenticated-orcid":false,"given":"Zenta","family":"Walther","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale University School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale Cancer Center , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, CT 06510 ,","place":["United States"]},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Health System , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-6905","authenticated-orcid":false,"given":"Joshua D","family":"Wallach","sequence":"additional","affiliation":[{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University , Atlanta, GA 30322 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026082010364525300_qxag203-B1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/edbk_174176","article-title":"Precision oncology: who, how, what, when, and when not?","volume":"37","author":"Schwartzberg","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1-2","key":"2026082010364525300_qxag203-B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000499109","article-title":"Development and validation of molecular assays for limited tissue samples","volume":"64","author":"Sussman","year":"2020","journal-title":"Acta Cytol"},{"key":"2026082010364525300_qxag203-B3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/po.20.00048","article-title":"Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology","volume":"4","author":"Hsiao","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"2026082010364525300_qxag203-B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.19963","article-title":"Biomarker testing approaches, treatment selection, and cost of care among adults with advanced cancer","volume":"8","author":"DaCosta Byfield","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"8","key":"2026082010364525300_qxag203-B5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13864 women in seven randomised trials","volume":"22","author":"Early Breast Cancer Trialists' Collaborative group (EBCTCG)","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026082010364525300_qxag203-B6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non\u2013small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2026082010364525300_qxag203-B7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3322\/caac.21774","article-title":"Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: a national lung cancer roundtable best-practice guide","volume":"73","author":"Fox","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2026082010364525300_qxag203-B8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"2026082010364525300_qxag203-B9","author":"National Comprehensive Cancer Network"},{"key":"2026082010364525300_qxag203-B10","author":"National Comprehensive Cancer Network"},{"key":"2026082010364525300_qxag203-B11","author":"National Comprehensive Cancer Network"},{"issue":"3","key":"2026082010364525300_qxag203-B12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2026082010364525300_qxag203-B13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/jco.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026082010364525300_qxag203-B14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1535370217740861","article-title":"The FDA oncology center of excellence and precision medicine","volume":"243","author":"Goldberg","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026082010364525300_qxag203-B15","author":"National Comprehensive Cancer Network"},{"issue":"9","key":"2026082010364525300_qxag203-B16","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"2026082010364525300_qxag203-B17","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2026082010364525300_qxag203-B18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cpt.955","article-title":"Clinical and regulatory aspects of companion diagnostic development in oncology","volume":"103","author":"J\u00f8rgensen","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2026082010364525300_qxag203-B19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review","volume":"27","author":"Mirza","year":"2024","journal-title":"Value Health."},{"issue":"1","key":"2026082010364525300_qxag203-B20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/jnci\/djae196","article-title":"Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting","volume":"117","author":"Stackland","year":"2025","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"2026082010364525300_qxag203-B21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaoncol.2020.7987","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol."},{"issue":"3","key":"2026082010364525300_qxag203-B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014872.pub2","article-title":"Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer","volume":"3","author":"Kazmi","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026082010364525300_qxag203-B23","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00715","article-title":"Comprehensive review on the clinical impact of next-generation sequencing tests for the management of advanced cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"2026082010364525300_qxag203-B24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jval.2018.06.011","article-title":"From the past to the present: insurer coverage frameworks for next-generation tumor sequencing","volume":"21","author":"Trosman","year":"2018","journal-title":"Value Health."},{"issue":"4","key":"2026082010364525300_qxag203-B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.5785","article-title":"Claim denials for cancer-related next-generation sequencing in Medicare","volume":"8","author":"Kang","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"15","key":"2026082010364525300_qxag203-B26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMp2035905","article-title":"No more surprises \u2014 new legislation on out-of-network billing","volume":"384","author":"Chhabra","year":"2021","journal-title":"N Engl J Med."},{"issue":"7","key":"2026082010364525300_qxag203-B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19110","article-title":"Opportunities for improving system-level barriers to biomarker testing for metastatic colorectal cancer","volume":"7","author":"Adekunle","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2026082010364525300_qxag203-B28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/ms9.0000000000002865","article-title":"Healthcare debts in the United States: a silent fight","volume":"87","author":"Aborode","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"15","key":"2026082010364525300_qxag203-B29","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/cncr.34271","article-title":"State legislative trends related to biomarker testing","volume":"128","author":"Sadigh","year":"2022","journal-title":"Cancer"},{"key":"2026082010364525300_qxag203-B30","author":"Centers for Medicare & Medicaid Services"},{"issue":"6","key":"2026082010364525300_qxag203-B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17818","article-title":"Commercial price variation for common services in general surgery","volume":"8","author":"Philips","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"12","key":"2026082010364525300_qxag203-B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.4025","article-title":"Facility fees for colonoscopy procedures at hospitals and ambulatory surgery centers","volume":"4","author":"Wang","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"1","key":"2026082010364525300_qxag203-B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.49581","article-title":"Large variations in the prices of urologic procedures at academic medical centers 1 year after implementation of the price transparency final rule","volume":"6","author":"Gul","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2026082010364525300_qxag203-B34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamasurg.2022.6402","article-title":"Commercial price variation for breast reconstruction in the era of price transparency","volume":"158","author":"Rochlin","year":"2023","journal-title":"JAMA Surg."},{"issue":"1","key":"2026082010364525300_qxag203-B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.52939","article-title":"Commercial price variation for 11 outpatient-based psychiatric services","volume":"9","author":"King","year":"2026","journal-title":"JAMA Netw Open."},{"issue":"3","key":"2026082010364525300_qxag203-B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0736","article-title":"Transparency and variability in pricing for pediatric outpatient imaging in US children's hospitals","volume":"5","author":"Hayatghaibi","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2026082010364525300_qxag203-B37","author":"National Cancer Institute"},{"key":"2026082010364525300_qxag203-B38","author":"Turquoise Health"},{"key":"2026082010364525300_qxag203-B39","author":"Turquoise Health"},{"key":"2026082010364525300_qxag203-B40","author":"Turquoise Health"},{"issue":"1","key":"2026082010364525300_qxag203-B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin."},{"key":"2026082010364525300_qxag203-B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114225","article-title":"Empowering effective biomarker-driven precision oncology: a call to action","volume":"209","author":"Lawler","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026082010364525300_qxag203-B43","author":"Centers for Medicare & Medicaid Services"},{"key":"2026082010364525300_qxag203-B44","author":"American Medical Association"},{"key":"2026082010364525300_qxag203-B45","author":"U.S. Centers for Disease Control and Prevention"},{"issue":"10","key":"2026082010364525300_qxag203-B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22914","article-title":"Assessment of changes in rural and urban primary care workforce in the United States from 2009 to 2017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2026082010364525300_qxag203-B47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031982","article-title":"Assessment of price variation in coronary artery bypass surgery at US hospitals","volume":"13","author":"Wei","year":"2024","journal-title":"J Am Heart Assoc."},{"key":"2026082010364525300_qxag203-B48","author":"Centers for Medicare & Medicaid Services"},{"issue":"10","key":"2026082010364525300_qxag203-B49","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/mlr.0000000000001761","article-title":"Hospital price transparency in the United States: an examination of chargemaster, cash, and negotiated, price variation for 14 common procedures","volume":"60","author":"Linde","year":"2022","journal-title":"Med Care"},{"issue":"9","key":"2026082010364525300_qxag203-B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3020","article-title":"Understanding variation in negotiated rates using novel health plan price transparency data","volume":"5","author":"Oakes","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"1","key":"2026082010364525300_qxag203-B51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamainternmed.2021.6445","article-title":"Payer-specific negotiated prices for prescription drugs at top-performing US hospitals","volume":"182","author":"Feldman","year":"2022","journal-title":"JAMA Intern Med."},{"issue":"4","key":"2026082010364525300_qxag203-B52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMsa2306609","article-title":"Hospital prices for physician-administered drugs for patients with private insurance","volume":"390","author":"Robinson","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"2026082010364525300_qxag203-B53","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamasurg.2021.0590","article-title":"Analysis of price transparency for oncologic surgery among national cancer institute\u2013designated cancer centers in 2020","volume":"156","author":"Xiao","year":"2021","journal-title":"JAMA Surg."},{"issue":"5","key":"2026082010364525300_qxag203-B54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1377\/hlthaff.2022.01184","article-title":"Insurer market power and hospital prices in the US","volume":"42","author":"LoSasso","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"2026082010364525300_qxag203-B55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/10775587231193475","article-title":"Do insurers with greater market power negotiate consistently lower prices for hospital care? Evidence from hospital price transparency data","volume":"81","author":"Wang","year":"2024","journal-title":"Med Care Res Rev"},{"issue":"1","key":"2026082010364525300_qxag203-B56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/qje\/qjy020","article-title":"The price ain\u2019t right? Hospital prices and health spending on the privately insured","volume":"134","author":"Cooper","year":"2019","journal-title":"Q J Econ."},{"key":"2026082010364525300_qxag203-B57","author":"Centers for Medicare & Medicaid Services"},{"key":"2026082010364525300_qxag203-B58","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1200\/po.21.00109","article-title":"Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study","volume":"5","author":"Gardner","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"2026082010364525300_qxag203-B59","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1377\/hlthaff.2016.0986","article-title":"Mystery of the chargemaster: examining the role of hospital list prices in what patients actually pay","volume":"36","author":"Batty","year":"2017","journal-title":"Health Aff (Millwood)."},{"issue":"3","key":"2026082010364525300_qxag203-B60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1200\/op.23.00153","article-title":"Importance of patient health insurance coverage and out-of-pocket costs for genomic testing in oncologists' treatment decisions","volume":"20","author":"Yabroff","year":"2024","journal-title":"JCO Oncol Pract."},{"issue":"4","key":"2026082010364525300_qxag203-B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.5585","article-title":"Trends and disparities in the use of next-generation sequencing in patients with cancer in the United States","volume":"9","author":"Hage Chehade","year":"2026","journal-title":"JAMA Netw Open."},{"key":"2026082010364525300_qxag203-B62","author":"Centers for Medicare & Medicaid Services"},{"issue":"6","key":"2026082010364525300_qxag203-B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20694","article-title":"Provision of hospital price information after increases in financial penalties for failure to comply with a US federal hospital price transparency rule","volume":"6","author":"Kong","year":"2023","journal-title":"JAMA Netw Open."},{"key":"2026082010364525300_qxag203-B64","author":"U.S. Department of Health and Human Services, Office of Inspector General"},{"issue":"3","key":"2026082010364525300_qxag203-B65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamaoncol.2019.5690","article-title":"Analysis of price transparency via national cancer institute\u2013designated cancer centers' chargemasters for prostate cancer radiation therapy","volume":"6","author":"Agarwal","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"2026082010364525300_qxag203-B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40526","article-title":"Comparison of US hospital cash prices and commercial negotiated prices for 70 services","volume":"4","author":"Jiang","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2026082010364525300_qxag203-B67","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14329","article-title":"Trends in hospital price transparency after implementation of the CMS final rule","volume":"59","author":"Brant","year":"2024","journal-title":"Health Serv Res"},{"key":"2026082010364525300_qxag203-B68","author":"Centers for Medicare & Medicaid Services"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxag203\/70502755\/qxag203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/8\/qxag203\/70502755\/qxag203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/8\/qxag203\/70502755\/qxag203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:37:35Z","timestamp":1787236655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxag203\/8752965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxag203","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"qxag203"}}